Clinical trials: Immunity to COVID-19
Covid19, Cancer
A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study
This is a single centre prospective observational study to assess the immune response to SARS-CoV-2 vaccines in cancer patients receiving active treatment or in follow-up at the IOSI and in non-cancer patients (age and gender…
- Trial name
- NCT04800146
- Testing
- Blood sample
- Where
- Switzerland
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Ilaria Colombo
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
SAR-CoV-2, Cellular Immune Response
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
Twelve months after the first SARS-CoV-2 cases in Wuhan, the FDA approved the first COVID-19 vaccine (Pfizer-BioNTech). Early studies on healthcare workers showed that antibody levels, especially against the Spike protein…
- Conditions
- SAR-CoV-2, Cellular Immune Response, Antibody Response
- Trial name
- BioVAC-immunit (NCT07049497)
- Testing
- Evaluation of the T cell response in terms of IFN-γ measured by ELISpot
- Where
- Italy
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Vaccine Response, COVID-19 Vaccine
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine.
- Conditions
- Vaccine Response, COVID-19 Vaccine, Immune Response to Covid 19 Vaccination
- Trial name
- NCT06821100
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1)
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Covid19, Immunosuppression
Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals
Currently, the efficacy of COVID-19 vaccination in immunodeficient patients is unknown. Here the investigators aim to evaluate the efficacy of COVID-19 vaccines in immunodeficient patients compared to healthy controls.
- Trial name
- CoVVac (NCT04858607)
- Testing
- Blood sample, Saliva sample
- Where
- Austria
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
Cancer, Hematopoietic System--Cancer
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.
- Conditions
- Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy
- Trial name
- NCT05164016
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew
COVID-19, Vaccine Reaction
Modification of the COVID-19 Vaccine Response by an Intervention on the Intestinal Flora
The elderly, who are often in poorer health, have been particularly affected by the COVID-19 pandemic. Recent study results show that while vaccines have been very effective in the short term, protection for the elderly may not…
- Conditions
- COVID-19, Vaccine Reaction, Elderly
- Trial name
- PIRATES-COV (NCT05195151)
- Where
- Canada
- Volunteers
- 592 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Chronic Lymphocytic Leukemia, COVID-19
Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL
Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy affecting older adults. CLL patients are immunocompromised by the disease itself and by several of its therapies.
- Trial name
- PACE-CLL (NCT05465876)
- Testing
- EVUSHELD
- Where
- Canada
- Sponsor
- Sunnybrook Health Sciences Centre
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
COVID-19, Virus Diseases
Bacillus Calmette-guérin Vaccination to Prevent COVID-19
Based on findings of the interim analysis of the ACTIVATE study showing 53% decrease of the incidence of all new infections with BCG vaccination, a new trial is designed aiming to validate if BCG can protect against COVID-19…
- Conditions
- COVID-19, Virus Diseases, Corona Virus Infection, Coronary Heart Disease
- Trial name
- ACTIVATEII (NCT04414267)
- Testing
- BCG vaccine
- Where
- 15 sites in Greece
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Covid19
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19
Age is the main risk factor associated with the severity of COVID-19. From the beginning of the vaccination campaign, elderly subjects are part of the priority population.
- Trial name
- COVIMMUNAGE (NCT05047718)
- Testing
- COVID-19 vaccine Pfizer (3 doses), COVID-19 vaccine Pfizer (2 doses), COVID-19 mRNA Vaccine Moderna (3 doses)
- Where
- 2 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Gut Microbiota, COVID-19 Vaccine
Modulation of Gut Microbiota to Enhance Health and Immunity
The novel coronavirus infection (COVID-19) caused by the SARS-CoV-2 virus is now a pandemic and has culminated major morbidity and mortality globally.
- Trial name
- NCT04884776
- Testing
- Microbiome immunity formula
- Where
- Hong Kong
- Volunteers
- 453 people
- Sponsor
- Chinese University of Hong Kong
Respiratory Tract Infections (RTI), Mucosal Immunity
To Evaluate Mucosal and Systematic Immune Response to Acute Respiratory Tract Infections of South African Children
The goal of this observational study is to answer a few questions about respiratory tract infections in South African children: 1.
- Trial name
- Muco-Kids (NCT06902194)
- Where
- 2 sites in South Africa
- Volunteers
- 250 people
- Sponsor
- Desmond Tutu TB Centre
COVID-19, Vaccination
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
Background: Vaccines against SARS-CoV-2, the virus that causes COVID-19, have been highly effective against preventing severe disease. But the protective effects of these vaccines appear to wane over time.
- Conditions
- COVID-19, Vaccination, Healthy Volunteer
- Trial name
- NCT05078905
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
In response to the COVID-19 pandemic, several vaccines (Pfizer, Moderna, Astrazeneca, Janssen) have been developed and are being administered to millions of people in France and billions around the world through massive…
- Trial name
- CoviCompare_J (NCT05037266)
- Testing
- COVID-19 Vaccine Janssen (Ad26.COV2-S)
- Where
- 10 sites in France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne